Psilocybin acts on the 5-HT2A and the 5-HT2C receptors. 5-HT2A receptors are largely responsible for producing hallucinogenic effects, and the 5-HT2C receptors are responsible for appetite control.
By hitting both receptors, NeonMind believes psilocybin will be instrumental in treating obesity, a disease that afflicts 650 million people globally.
Read More
The Guardian spoke with Robin Carhart-Harris on the therapeutic potential of psychedelic medicines.
Read More
The Seattle-based start-up raised US$22m to push its proprietary compounds through clinical trials.
Read MoreWesana Health gives MAPS US$1.5m to study traumatic brain injury.
MYND closes US$3m non-brokered private placement offering.
Levitee Labs starts trading on the OTC market under LVTTF.
Blossom’s takeaways from MIND Foundation’s INSIGHT 2021 conference.
NeonMind completes sale of consumer division assets for C$1.1m and royalties.
Perception Neuroscience starts Phase II clinical trials for treatment-resistant depression.
Psyched Wellness starts preclinical trials on amanita muscaria derivative.
Hamilton Morris joins COMPASS Pathways as a consultant and advisor.
Field Trip to focus on postpartum and treatment-resistant depression with FT-104.
PharmaTher shares update on drug development pipeline.
Mindset Pharma releases research data on proprietary psilocybin derivative.
COMPASS Pathways acquires IP portfolio of novel compounds and prodrugs.
atai Life Sciences and Introspect Digital Therapeutics test technology in ketamine treatments.
Ketamine One enters agreement with Illumma LLC for ketamine infusion clinics.
Mount Sinai’s centre for psychedelic research receives US$5m grant.
The impact and importance of psychedelic medicine.
Algernon Pharmaceuticals confirms DMT increased growth of neurons by 40%.
LSD-triggered altered behaviours linked to abnormal brain communication.
A psychedelic renaissance could fill a treatment gap for psychiatric disorders.
Mind Medicine Australia launches course on fundamentals of psychedelic-assisted therapy.
University of Wisconsin creates psychedelic medicine research centre.
Could ketamine be a cure for some mental health problems?
Intranasal ketamine could effectively treat phantom pain.
MDMA-assisted couples therapy may help maximise recovery from PTSD.
Detroit to decide on decriminalisation of psychedelics in November.
California senator outlines next steps for decriminalisation after bill stalls.